Senti Biosciences (NASDAQ:SNTI) Shares Down 3.2% – What’s Next?

Senti Biosciences, Inc. (NASDAQ:SNTI) shares fell 3.2% during mid-day trading on Thursday . The company traded as low as $0.4203 and last traded at $0.4266. Approximately 117,052 shares traded hands during mid-day trading, a decline of 67% from the average daily volume of 356,246 shares. The stock had previously closed at $0.4405.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. Chardan Capital raised their price objective on Senti Biosciences from $11.00 to $12.00 and gave the company a “buy” rating in a research report on Friday, May 15th. Wall Street Zen raised shares of Senti Biosciences from a “strong sell” rating to a “hold” rating in a research report on Saturday, March 28th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Senti Biosciences in a research note on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $10.00.

Senti Biosciences Stock Down 5.3%

The firm has a market capitalization of $12.58 million, a PE ratio of -0.21 and a beta of 2.04. The firm’s fifty day simple moving average is $0.91 and its 200-day simple moving average is $0.95.

Senti Biosciences (NASDAQ:SNTI) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.22. The firm had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.02 million. As a group, analysts predict that Senti Biosciences, Inc. will post -1.53 earnings per share for the current year.

Institutional Trading of Senti Biosciences

A number of institutional investors and hedge funds have recently modified their holdings of the business. Jane Street Group LLC bought a new position in shares of Senti Biosciences during the fourth quarter valued at $40,000. Virtu Financial LLC purchased a new stake in shares of Senti Biosciences during the 4th quarter valued at about $46,000. Citadel Advisors LLC purchased a new stake in shares of Senti Biosciences during the 3rd quarter valued at about $117,000. Geode Capital Management LLC grew its stake in shares of Senti Biosciences by 395.6% in the second quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock worth $311,000 after acquiring an additional 117,588 shares during the period. Finally, Armistice Capital LLC bought a new stake in shares of Senti Biosciences in the second quarter worth approximately $1,883,000. Institutional investors own 25.70% of the company’s stock.

About Senti Biosciences

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.